On September 9^th, 2017, 1^stCongress of the Society for Triglyceride Biology and Medicine was held at Osaka. Dr. NAKATANI, head of global clinical research support office, participated in the session of triglyceride deposit cardiomyovasculopathy (TGCV) as a chairman. As you may know TGCV was found in 2008 by Dr. Ken-ichi HIRANO working for Osaka University Graduate School of Medicine, Department of Cardiovascular Medicine, and consists of 2 subtypes; primary and idiopathic TGCV. The number of patients in worldwide who are suffering from primary or idiopathic TGCV estimate approximately 100 or 40000, respectively. Although prognosis of patients with idiopathic TGCV is under investigation, we recognize that patients with primary TGCV mainly occur cardiovascular death aged between 20-60 years of their age, despite under maximum effort of the treatment. In the session, we discussed concept, diagnosis, treatment, global trial, and perspective of both primary and idiopathic TGCV. The end of the session, Dr. NAKATANI told as a closing remark that we need hopefully to collect, share and disseminate information related to TGCV through the congress in order to overcome the disease as soon as possible.

Dr. Hirano’s Presentation

Dr. NAKATANI acted as a chairman in the TGCV session